FOX Translator

Detach

No data currently available.

No data currently available.

SYMBOL

 
Dividends

You know that buying a stock makes you part owner of a company, theoretically with millions of other people. But, while ownership has its privileges (at minimum you get a neat stock certificate and an invitation to the annual meeting), being an owner doesn't necessarily pay. Sure, you make money if the stock goes up, but only if you sell, and you can, in theory, lose all the value of your investment if the stock tanks.

Enter the dividend. Here, you get money simply from holding the stock. Companies pay a yield, which is expressed in a percentage based on the stock's price. For example, if a stock trades at $10, and pays a 10% annual yield, your dividend payment would be a $1. (Usually, companies break out the payments quarterly, so, using our example, you¿d get, well, a quarter each quarter.)

Companies that pay dividends fall into a few categories. First, you've got your big, stable companies that generate enough cash that it makes sense to throw some back to shareholders. Next, there are businesses, like real estate investment trusts, that are in the business of sitting back and receiving cash, then distributing it to holders. And, then there are companies that need to dangle a high dividend yield like a carrot to ease investor fears. Cigarette-maker Altria has been doing this for years.

Simply because a company pays a dividend doesn't make it a good investment. After all, you may want to take a chance on a growth stock that can move higher in price than dividend payers are known to do. But, you can¿t beat the safety of knowing that, even if a stock doesn't move in a year, you¿re at least making something off your investment.

Home / Markets / Industries / Health Care

Barr Pharma To License 2 Contraceptives From Bayer

 
Robert Daniel
MarketWatch Pulse
 

TEL AVIV -- Barr Pharmaceuticals Inc., the Montvale, N.J., drugmaker, said its Barr Laboratories subsidiary entered supply and licensing agreements regarding generic versions of Bayer AG's Yasmin and Yaz oral contraceptives. Terms weren't disclosed. Under the accord, Bayer will supply Barr with the generic versions so it can begin marketing them before the patents that protect the products expire, Barr said. Barr will have sole responsibility to market and sell the products in the U.S. under the Barr Laboratories label. Bayer plans to continue to appeal a March 3, 2008, decision by the U.S. District Court in New Jersey that invalidated the Yasmin patent. But Barr said that whatever the final outcome of that case, the deal with Bayer ensures that it can continue to sell the generic versions of Yasmin and Yaz. Barr Labs had challenged the patent in the New Jersey federal court. A month later, Barr appealed the decision to the U.S. Court of Appeals for the Federal Circuit in Washington.

Copyright © 2008 MarketWatch, Inc.

 

Market Snapshot

Symbol Last Price Netchange Volume
-- -- -- --
-- -- -- --
-- -- -- --
-- -- -- --
-- -- -- --